BioCryst Pharmaceuticals, Inc. (BCRX) Social Stream



BioCryst Pharmaceuticals, Inc. (BCRX): $10.84

0.26 (+2.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BCRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Featured Post From StockTwits About BCRX

$BCRX To give people some context about our upcoming P3. Apellis Pharmaceuticals dosed it’s first patient in it’s head to head PNH study in June of 2018, and by June of 2019 enrollment was completed. In May of 2020 they were submitting to the FDA for an NDA for PNH based off what at the time was pretty compelling data. The stock price rose around 200% from 2018 to 2020 as they showed successful data(despite numerous offerings and Covid). Unlike BCRX they had no other approved drugs on market during that time and now they have roughly a 5.3 billion dollar market cap. With our current success in HAE plus our future success in PNH we will be sitting on a 10 billion dollar market cap in roughly 1-2 years maximum that’s 55-60 dollars minimum. Add in the rest of our impressive pipeline demonstrating success and we could be much higher. I love the basket trial announcement. It will allow us to move faster on many of these indications. Have a great weekend. 💊 💊 💊
Psween, published August 15, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3328 seconds.